Program 1: Cancer Genes and Pathways

在新重组的癌症基因和途径（CGP）计划的研究重点是研究 具有生物学意义的遗传变异和癌症发展的分子途径， 免疫监视这个基础科学计划的主要目标是更好地了解基本的 肿瘤发生和癌症免疫学的机制，从而定义新的分子实体， 作为疾病生物标志物和/或创新的抗癌疗法。这是通过三个 重叠的研究主题集中在1）基因组组织，调控和癌症基因表达，2） 细胞增殖、存活和转化，和3）肿瘤免疫监视。关键科学 上一个资助期的成就包括在理解受损DNA机制方面的进展 修复和复制，鉴定和表征新的肿瘤促进遗传改变， 癌症基因网络，癌症的创新动物模型的开发，以及途径的确定 控制B和T淋巴细胞的存活和活化。CGP成员包括54名正式成员和6名准成员 成员跨越16个部门（10个基础科学，6个临床）在3个学院。年度CGP供资总额 在上一个预算年度，同行评审研究的费用为1036万美元（NCI资助2.00美元）， 非同行评审的研究项目。CGP成员高度协作，撰写或共同撰写 过去4年中，353篇癌症相关同行评审出版物，17%（n=59）为项目内出版物，22%为 （n=77）方案间，32%（n=113）机构间。49篇稿件出现在高影响力 期刊（影响因子>10）。富有成效的方案内/方案间和多机构小组正在发挥主导作用 成熟B系肿瘤（骨髓瘤和非霍奇金淋巴瘤）和神经内分泌肿瘤的研究进展 研究，并对其他人类恶性肿瘤，包括白血病，乳腺癌， 前列腺癌、黑色素瘤、胰腺癌和肝癌。

Research in the newly restructured Cancer Genes and Pathways (CGP) program focuses on the study of biologically significant genetic alterations and molecular pathways that underlie cancer development and immune surveillance. The primary goal of this basic science program is to better understand fundamental mechanisms of tumorigenesis and cancer immunology, thereby defining new molecular entities that can be exploited as disease biomarkers and/or innovative anti-cancer therapies. This is accomplished through three overlapping research themes centered on 1) genome organization, regulation and cancer gene expression, 2) cellular proliferation, survival and transformation, and 3) tumor immunosurveillance. Key scientific achievements over the prior funding period include advances in understanding mechanisms of damaged DNA repair and replication, identification and characterization of novel tumor-promoting genetic alterations and cancer gene networks, development of innovative animal models of cancer, and determination of pathways controlling B and T lymphocyte survival and activation. CGP membership includes 54 full and 6 associate members spanning 16 departments (10 basic science, 6 clinical) across 3 colleges. Annual CGP total funding for peer-reviewed research in the last budget year was $10.36 million ($2.00 NCI funding) and $1.99 million for non-peer-reviewed research projects. CGP members are highly collaborative having authored or co-authored 353 cancer-related peer-reviewed publications in the past 4 years, with 17% (n=59) intra-programmatic, 22% (n=77) inter-programmatic, and 32% (n=113) inter-institutional. 49 manuscripts appeared in high impact journals (Impact Factor >10). Productive intra-/inter-programmatic and multi-institutional groups are leading advances in mature B lineage tumors (myeloma and non-Hodgkin's lymphomas) and neuroendocrine tumor research, and making major contributions to other human malignancies including leukemias, breast cancer, prostate cancer, melanoma, pancreatic adenocarcinoma and liver cancers.